SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. COVID-19 has highly
variable disease severity and a bimodal course characterized by acute respiratory viral …

Acting on the cytokine cascade is key to preventing disease progression and death in
hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 …

Abstract Interleukin-6 (IL-6) is a multi-tasking cytokine that represents high activity in patients
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cancer. High …

В середине 2021 года инфекция SARS-CoV-2 (Severe Acute Respiratory coronavirus 2),
вызвавшая пандемию коронавирусной болезни 2019 (coronavirus disease, COVID-19) …

Background The recent emergence of COVID-19, rapid worldwide spread, and incomplete
knowledge of molecular mechanisms underlying SARS-CoV-2 infection have limited …

Пандемия коронавирусной болезни 2019 (coronavirus disease, COVID-19),
этиологически связанной с вирусом SARS-CoV-2 (severe acute respiratory syndrome …

It is well established that pre-existing comorbid conditions such as hypertension, diabetes,
obesity, cardiovascular diseases (CVDs), chronic kidney diseases (CKDs), cancers, and …

Tocilizumab is an interleukin (IL)‐6 receptor inhibitor that has been proposed as a
therapeutic agent for treating coronavirus disease 2019 (COVID‐19). The aim of this …

Two years have passed since WHO declared a pandemic state for SARS-CoV-2 infection.
COVID-19 pathogenesis consists of a first viral phase responsible for early symptoms …

The coronavirus 2019 pandemic (coronavirus disease, COVID-19), etiologically related to
the SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus-2), has once again …